<DOC>
	<DOCNO>NCT00708656</DOCNO>
	<brief_summary>The purpose study compare safety effectiveness dose mesalazine 800 mg tablet ( Asacol® ) 2.4 g daily versus divide dos three time daily maintenance remission ulcerative colitis .</brief_summary>
	<brief_title>The Colitis Once Daily Asacol Study</brief_title>
	<detailed_description>Study design - Multicentre , randomize , single-blind , comparator-controlled , parallel-armed study - One year follow-up , relapse ( whichever short ) - 40-60 UK centre Subject population - Ulcerative colitis remission ( sigmoidoscopy score 0 1 symptom active disease , treatment active colitis ) least 4 week , 2 year - Taking mesalazine sulfasalazine prior study entry - Patients exclude Crohn 's disease , symptom active colitis , use corticosteroid , ciclosporin oral/enema mesalazine past 4 week , intolerant mesalazine Asacol , pregnant lactating , know HIV , hepatic disease , renal impairment serious medical psychiatric illness - Sample size 250 - Gender : male female - Ethnicity : restriction - Age : 18 Test Product Once daily group : Asacol® 2.4g daily give three 800mg tablet orally qAM Three time daily group : Asacol® 2.4g daily give one 800mg tablet orally three time daily Criteria Evaluation : Primary Outcome Variable : Relapse rate 1 year intention treat population , study power detect non-inferiority once-daily regimen . Secondary Outcome Variables : assessment superiority once-daily regimen , non-inferiority demonstrate ; safety analysis ; per protocol analysis relapse rate ; time course relapse ; medication compliance ; change modify Baron sigmoidoscopy score trial entry relapse/12 month ; impact various factor relapse rate ( time last relapse study entry , concomitant azathioprine 6-mercaptopurine therapy ; disease extent ; disease duration ; smoke status ; age diagnosis ; previous dose mesalazine ; baseline calprotectin ; baseline CRP level ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patients meet follow criterion eligible study entry : Male female patient age 18 ulcerative colitis confirm histology remission ( symptom active disease , modify Baron sigmoidoscopic score 0 1 ) If female , must ( documented patient note ) : postmenopausal ( least 1 year without spontaneous menses ) , surgically sterile ( tubal ligation hysterectomy least 6 month prior enrollment ) , use acceptable contraception ( e.g. , oral , intramuscular , implanted hormonal contraception ) least 3 month prior enrollment , sexual partner nonreversed vasectomy ( confirm azoospermia ) , use 1 barrier method ( e.g. , condom , diaphragm , spermicide , intrauterine device ) Patients whose ulcerative colitis clinical remission 4 week longer , symptomatic relapse within past two year Patients take mesalazine , sulfasalazine drug contain 5ASA 4 week longer Patients capable give write informed consent The following patient exclude study : Patients Crohn 's disease Patients symptom active colitis Modified Baron sigmoidoscopy score 2 3 Patients used oral , enema , intravenous suppository preparation corticosteroid , oral intravenous ciclosporin , mesalazine enema suppository within past four week Patients take azathioprine 6mercaptopurine alter dose start treatment within past three month , ( drug permit stable dose study ) Patients intolerance Asacol 400 mg mesalazine Women pregnant lactating Patients know HIV infection Patients hepatic disease Patients renal impairment ( creatinine local reference range ) , positive urine dipstick test blood protein Other serious medical psychiatric illness opinion investigator would possibly comprise study Patients problem alcohol excess drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>IBD</keyword>
	<keyword>Colitis</keyword>
	<keyword>UC</keyword>
</DOC>